title: Interactions of atrial and brain natriuretic peptides at pathophysiological levels in normal men.
abstract: Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are both circulating plasma hormones that are secreted by the heart and have similar physiological effects. We have shown previously that abrupt increases in plasma BNP in normal humans impair the clearance of ANP from plasma and result in additive physiological effects. Because large increases in plasma ANP are reported to have no effect on plasma BNP levels in patients with heart failure, we have studied ANP-BNP interactions in eight normal male subjects receiving background infusions of BNP (2 pmol.kg-1.min-1 for 5 h). Each subject also received a coinfusion of ANP ("active" day, 2 pmol.kg-1.min-1 for 2 h) or vehicle ("placebo" day) using a balanced random order, single-blind design. Metabolic clearance rate of ANP (mean 4.1 +/- 0.6 l/min) and disappearance rate from the plasma (t1/2 3.4 +/- 0.3 min) were similar to values measured previously in the absence of exogenous BNP. In contrast, steady-state plasma BNP levels were reversibly increased (mean BNP increment 10 pmol/l) during the administration of ANP (P = 0.038). Associated with these changes were significant (additive) physiological effects. Thus the addition of ANP increased plasma and urine guanosine 3',5'-cyclic monophosphate (P < 0.001 for both) and lowered systolic blood pressure (P = 0.049). When ANP was coinfused, significant differences were also observed in urine volume (P = 0.001) and sodium excretion (P = 0.043) between the infusion period (when urine volume and sodium excretion were enhanced) and postinfusion period (when values decreased). Taken together, our findings of similar interactions between ANP-BNP and BNP-ANP infusions occurring at pathophysiological concentrations of these two peptides, suggest that the interactions result from dissociation of prebound hormone, presumably from biological or clearance receptors.
authors.affiliation: Department of Endocrinology, Christchurch Hospital, New Zealand.
authors.forename: P J
authors.initials: PJ
authors.lastname: Hunt
authors.forename: E A
authors.initials: EA
authors.lastname: Espiner
authors.forename: A M
authors.initials: AM
authors.lastname: Richards
authors.forename: T G
authors.initials: TG
authors.lastname: Yandle
authors.forename: C
authors.initials: C
authors.lastname: Frampton
authors.forename: M G
authors.initials: MG
authors.lastname: Nicholls
mesh_terms: D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood* / Q000494:pharmacology / Q000502:physiology*; D001794:Blood Pressure; D002303:Cardiac Output, Low / Q000097:blood; D006152:Cyclic GMP / Q000097:blood; D006728:Hormones / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009318:Natriuresis; D020097:Natriuretic Peptide, Brain; D009419:Nerve Tissue Proteins / Q000097:blood* / Q000494:pharmacology / Q000502:physiology*; D009994:Osmolar Concentration; D012016:Reference Values; D014556:Urine / Q000737:chemistry
chemical_list: D006728:Hormones; D009419:Nerve Tissue Proteins; D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D006152:Cyclic GMP